Glucan particles are a powerful adjuvant for the HBsAg, favoring antiviral immunity.

08:00 EDT 9th April 2019 | BioPortfolio

Summary of "Glucan particles are a powerful adjuvant for the HBsAg, favoring antiviral immunity."

The lack of vaccine adjuvants that are able to induce robust T cell responses fosters the search for more powerful options. Pathogen-like particles are a promising approach. The adjuvant activity of pathogen-like particles is highly influenced by size and surface composition. This study aimed to evaluate the adjuvant potential of two different β-glucan-based particles: blend chitosan/β-glucan particles (ChiGluPs), which are positively charged and have mean size of 1276 nm, and neutral yeast-derived glucan particles (GPs) with a mean size of 3 µm. Additionally, chitosan particles (ChiPs) were used to understand the effect of β-glucan addition (ChiGluPs). Mouse spleen cells responded through the production of either TNF-α or RANTES, following in vitro stimulation with particles containing either β-glucan (ChiGluPs and GPs) or chitosan (ChiGluPs and ChiPs). Human monocytes responded to all particles through TNF-α secretion. Subcutaneous vaccination of mice with the hepatitis B surface antigen (HBsAg) showed increased serum IgG for all particles compared to HBsAg alone (435-fold, 4500-fold or 2500-fold increase for either ChiPs, ChiGluPs or GPs). Interestingly, only GPs elicited the secretion of HBsAg-specific Th1, Th2, Th9, Th17, Th22 and Treg related cytokines. This study demonstrates, for the first time, that GPs can have a significant role against the hepatitis B virus, by favoring antiviral immunity.


Journal Details

This article was published in the following journal.

Name: Molecular pharmaceutics
ISSN: 1543-8392


DeepDyve research library

PubMed Articles [6739 Associated PubMed Articles listed on BioPortfolio]

Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells.

More than 290 million people have chronic HBV infection and are at risk of developing cirrhosis and hepatocellular carcinoma. HBV subviral particles are produced in large excess over virions in infect...

Comparative purification and characterization of hepatitis B virus-like particles produced by recombinant vaccinia viruses in human hepatoma cells and human primary hepatocytes.

This study describes the comparative expression and purification of hepatitis B surface antigen (HBsAg) particles produced upon infection of human primary hepatocytes and human hepatoma cell lines (Hu...

Feeding-regimen of β-glucan to enhance innate immunity and disease resistance of Nile tilapia, Oreochromis niloticus Linn., against Aeromonas hydrophila and Flavobacterium columnare.

β-glucan is one of the most potent immunostimulants enhancing innate immune activity, disease resistance and growth performance of many aquatic organisms. Nevertheless, there are few studies on feedi...

REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection.

Nucleic acid polymers (NAPs) are broad spectrum antiviral agents whose antiviral activity in HBV infection is derived from their ability to block the release of HBsAg. This pharmacological activity ef...

Metabolic Engineering of Saccharomyces cerevisiae to Improve Glucan Biosynthesis.

β-Glucan is a chief structural polymer of yeast cell wall. β-Glucan has attracted intensive attention because of its wide applications in health protection and cosmetic areas. In the present study, ...

Clinical Trials [3601 Associated Clinical Trials listed on BioPortfolio]

Impact of Hepatitis B Vaccination on HBs Antigenemia

- HBV is not curable with persistent HBsAg even after the disappearance of HBV DNA. - HBsAg > 1000 IU/ml is associated with the risk of virological recurrence and HCC. - There is ...

HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients

Chronic hepatitis B (CHB) affects more than 350 million people worldwide. The most common form in Europe is CHB HBeAg-negative. Antiviral treatment of CHB HBeAg-negative patients includes ...

HBV Envelope Proteins Variability on HBs Antigen Clearance Under Nucleos(t)Ide Analogue Therapy

Hepatitis B virus (HBV) infection remains difficult to eradicate with about 240 million people living with HBV chronic infection. HBsAg clearance, correlated with a good clinical prognosis...

Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.

The hepatitis B virus (HBV) infection rate among renal transplant recipients was reported from 3% to 20.9%. And patient survival and graft survival rates following renal transplantation ma...

The Effect of Insoluble Yeast Beta-glucan Intake on Pre-diabetic Patients

There is a lot of evidence to show that the yeast beta-glucan has immunomodulatory, anti-inflammatory, anti-infective effects.However,few work was done on the relationship between yeast ba...

Medical and Biotech [MESH] Definitions

An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria.

In glycogen or amylopectin synthesis, the enzyme that catalyzes the transfer of a segment of a 1,4-alpha-glucan chain to a primary hydroxy group in a similar glucan chain. EC

1,4-alpha-D-Glucan-1,4-alpha-D-glucan 4-alpha-D-glucosyltransferase/dextrin 6 alpha-D-glucanohydrolase. An enzyme system having both 4-alpha-glucanotransferase (EC and amylo-1,6-glucosidase (EC activities. As a transferase it transfers a segment of a 1,4-alpha-D-glucan to a new 4-position in an acceptor, which may be glucose or another 1,4-alpha-D-glucan. As a glucosidase it catalyzes the endohydrolysis of 1,6-alpha-D-glucoside linkages at points of branching in chains of 1,4-linked alpha-D-glucose residues. Amylo-1,6-glucosidase activity is deficient in glycogen storage disease type III.

An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.

Interferon-induced DYNAMIN-like GTP-binding proteins localized in the cytoplasm, nuclear pore complex and nucleus. They play a role in antiviral defense and immunity.

Quick Search


DeepDyve research library

Relevant Topics

Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...

Searches Linking to this Article